{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurologic+Diseases%2C+General&page=3",
    "query": {
      "condition": "Neurologic Diseases, General",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 439,
    "total_pages": 44,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurologic+Diseases%2C+General&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurologic+Diseases%2C+General&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:41:06.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04980495",
      "title": "An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis",
        "MG - Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2021-12-16",
      "completion_date": "2025-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 12,
      "location_summary": "Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980495"
    },
    {
      "nct_id": "NCT06699953",
      "title": "Characterizing the EEG Signature of Fentanyl and Its Association With Drug Liking",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Activity Related to Opioid Administration",
        "Brain Activity Related to Drug Liking"
      ],
      "interventions": [
        {
          "name": "Observational study in patients receiving fentanyl for surgery",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699953"
    },
    {
      "nct_id": "NCT07217587",
      "title": "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Nipocalimab",
          "type": "DRUG"
        },
        {
          "name": "Efgartigimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 115,
      "start_date": "2026-01-05",
      "completion_date": "2029-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 20,
      "location_summary": "Fullerton, California • Pomona, California • Colorado Springs, Colorado + 17 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07217587"
    },
    {
      "nct_id": "NCT07604038",
      "title": "Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) for Stress, Sleep, and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Resilience",
        "Systemic Inflammation",
        "General Wellbeing",
        "Sleep Quality",
        "Safety"
      ],
      "interventions": [
        {
          "name": "Mycolicibacterium petrae KGA-10 (heat-killed)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo (microcrystalline cellulose)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Kioga Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 107,
      "start_date": "2025-08-14",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 1,
      "location_summary": "Boulder, Colorado",
      "locations": [
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07604038"
    },
    {
      "nct_id": "NCT00056238",
      "title": "Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke",
        "Neurologic Diseases, General"
      ],
      "interventions": [
        {
          "name": "NC-758 (Anti amyloidotic [Aß] agent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bellus Health Inc. - a GSK company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 5,
      "location_summary": "Lexington, Kentucky • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056238"
    },
    {
      "nct_id": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cholangiocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Neoplasms",
        "Lymphoma, Large-Cell, Anaplastic",
        "Melanoma",
        "Neuroendocrine Tumors",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Papillary Thyroid Cancer",
        "Primary Brain Tumors",
        "Renal Cell Carcinoma",
        "Sarcomas",
        "Salivary Gland Cancers",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 534,
      "start_date": "2015-11-19",
      "completion_date": "2026-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568267"
    },
    {
      "nct_id": "NCT00104416",
      "title": "Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy, Tonic-Clonic"
      ],
      "interventions": [
        {
          "name": "lamotrigine (LAMICTAL) extended-release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2004-12",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 64,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104416"
    },
    {
      "nct_id": "NCT01607073",
      "title": "Verapamil as Therapy for Children and Young Adults With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "Verapamil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gillette Children's Specialty Healthcare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 2,
      "start_date": "2012-04",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota • Saint Paul, Minnesota + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01607073"
    },
    {
      "nct_id": "NCT00518713",
      "title": "Clobazam in Patients With Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Epilepsy, Generalized",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Clobazam Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Clobazam Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Clobazam High Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundbeck LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Years to 60 Years"
      },
      "enrollment_count": 238,
      "start_date": "2007-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-02-09",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 34,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518713"
    },
    {
      "nct_id": "NCT06411288",
      "title": "Global Study of Del-desiran for the Treatment of DM1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonia",
        "Myotonic Dystrophy Type 1 (DM1)",
        "Dystrophy Myotonic",
        "Myotonic Disorders",
        "Steinert Disease",
        "Steinert",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AOC 1001 (del-desiran)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 159,
      "start_date": "2024-05-30",
      "completion_date": "2026-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-11-19T00:41:06.431Z",
      "location_count": 18,
      "location_summary": "Stanford, California • Denver, Colorado • Gainesville, Florida + 15 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411288"
    }
  ]
}